NEW YORK – Paris-based biotech Transgene on Thursday said that the first head-and-neck cancer patient has been dosed with its individualized immunotherapy, TG4050, in a Phase I trial.
The cancer vaccine is personalized to each patient based on Transgene's Myvac viral vector-based immunotherapy platform and NEC's artificial intelligence-based Neoantigen Prediction System.